Comments
Loading...
Biomarin Pharmaceutical Stock Guidance | NASDAQ:BMRN | Benzinga
Biomarin Pharmaceutical issues guidance on future EPS and revenue, giving investors insight into how much the company expects to earn in upcoming periods.
| Get Alert | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 02/19/2025 | BMRN | Biomarin Pharmaceutical | FY | 2025 | $4.20 | $4.40 | $4.16 | $3.10B | $3.20B | $3.10B | Get Alert |
| 10/29/2024 | BMRN | Biomarin Pharmaceutical | FY | 2024 | $3.25 | $3.35 | $2.07 | $2.79B | $2.83B | $2.80B | Get Alert |
| 09/04/2024 | BMRN | Biomarin Pharmaceutical | FY | 2024 | $3.10 | $3.25 | $2.04 | $2.75B | $2.83B | $2.80B | Get Alert |
| 09/04/2024 | BMRN | Biomarin Pharmaceutical | FY | 2027 | — | — | — | $4.00B | $4.00B | — | Get Alert |
| 08/05/2024 | BMRN | Biomarin Pharmaceutical | FY | 2024 | $3.10 | $3.25 | $2.87 | $2.75B | $2.83B | $2.74B | Get Alert |
| 04/24/2024 | BMRN | Biomarin Pharmaceutical | FY | 2024 | $2.75 | $2.95 | $1.65 | $2.70B | $2.80B | $2.77B | Get Alert |
| 02/22/2024 | BMRN | Biomarin Pharmaceutical | FY | 2024 | $2.60 | $2.80 | $1.96 | $2.70B | $2.80B | $2.83B | Get Alert |
| 11/01/2023 | BMRN | Biomarin Pharmaceutical | FY | 2023 | $1.90 | $2.05 | $1.02 | $2.39B | $2.47B | $2.45B | Get Alert |
| 07/31/2023 | BMRN | Biomarin Pharmaceutical | FY | 2023 | $1.85 | $2.10 | $1.02 | $2.38B | $2.50B | $2.46B | Get Alert |
| 04/26/2023 | BMRN | Biomarin Pharmaceutical | FY | 2023 | $1.80 | $2.05 | $0.95 | $2.38B | $2.50B | $2.46B | Get Alert |
| 02/27/2023 | BMRN | Biomarin Pharmaceutical | FY | 2023 | $1.80 | $2.05 | $1.61 | $2.38B | $2.50B | $2.58B | Get Alert |
| 10/26/2022 | BMRN | Biomarin Pharmaceutical | FY | 2022 | — | — | — | $2.06B | $2.16B | $2.12B | Get Alert |
| 08/03/2022 | BMRN | Biomarin Pharmaceutical | FY | 2022 | — | — | — | $2.06B | $2.16B | $2.11B | Get Alert |
| 04/27/2022 | BMRN | Biomarin Pharmaceutical | FY | 2022 | — | — | — | $2.05B | $2.15B | $2.10B | Get Alert |
| 02/23/2022 | BMRN | Biomarin Pharmaceutical | FY | 2022 | — | — | — | $2.05B | $2.15B | $2.14B | Get Alert |
| 10/27/2021 | BMRN | Biomarin Pharmaceutical | FY | 2021 | — | — | — | $1.82B | $1.88B | $1.85B | Get Alert |
| 07/28/2021 | BMRN | Biomarin Pharmaceutical | FY | 2021 | — | — | — | $1.79B | $1.88B | $1.82B | Get Alert |
| 04/29/2021 | BMRN | Biomarin Pharmaceutical | FY | 2021 | — | — | — | $1.75B | $1.85B | $1.81B | Get Alert |
| 02/25/2021 | BMRN | Biomarin Pharmaceutical | FY | 2021 | — | — | — | $1.75B | $1.85B | $1.91B | Get Alert |
| 11/05/2020 | BMRN | Biomarin Pharmaceutical | FY | 2020 | — | — | — | $1.81B | $1.87B | $1.86B | Get Alert |
| 08/04/2020 | BMRN | Biomarin Pharmaceutical | FY | 2020 | — | — | — | $1.85B | $1.95B | $1.90B | Get Alert |
FAQ
What is the most recent guidance for Biomarin Pharmaceutical (BMRN)?
The most recent guidance for Biomarin Pharmaceutical (BMRN) was reported on February 19, 2025 for the full year 2025. The company provided earnings per share guidance in the range of $4.20 to $4.40, compared to the estimated EPS of $4.16. Additionally, Biomarin Pharmaceutical forecasted revenue between $3.10B and $3.20B for the quarter.
Browse guidance and forecast on all stocks.